BIRC5 and hepatocellular carcinoma: Ibulocydine (an isobutyrate prodrug of the CDKi, BMK-Y101) have shown strong anti-proliferative effects in hepatocellular carcinoma (HCC) xenograft mouse [210], which is again mediated by the down-regulation of survivin and other anti-apoptotic proteins.